<!DOCTYPE html><html><head><title>Choline3</title>
            <link rel="stylesheet" href="../css/style.css">
            
<script>
/* THE CITADEL PROTOCOL */
document.addEventListener('contextmenu', event => event.preventDefault());
document.addEventListener('keydown', function(event) {
    if (event.ctrlKey && (event.key === 'c' || event.key === 'u' || event.key === 's' || event.key === 'p' || event.key === 'a')) {
        event.preventDefault();
    }
    if (event.key === 'F12' || (event.ctrlKey && event.shiftKey && event.key === 'I')) {
        event.preventDefault();
    }
});
document.ondragstart = function() { return false; };
</script>
<style>
    body {
        -webkit-user-select: none;
        -moz-user-select: none;
        -ms-user-select: none;
        user-select: none;
    }
    img { pointer-events: none; }
</style>
<meta name="robots" content="noindex, nofollow, noarchive">
<!-- WARNING: PROTECTED CONTENT -->

            </head>
            <body>
            <div class="sidebar"><h3>CODEX OF COSMOS</h3><ul><li><a href='../index.html'>HOME</a></li><br><li><strong>MASTER PAPERS</strong></li><li><a href='../01-Master-Papers/01-Volume-1-The-Physics.html'>01-Volume-1-The-Physics.md</a></li><li><a href='../01-Master-Papers/03-The-Matrix.html'>The 128-Type Matrix</a></li><li><a href='../01-Master-Papers/04-The-Controls.html'>The Control Room</a></li><li><a href='../01-Master-Papers/05-The-Pathology.html'>The Cost of Error</a></li><li><a href='../01-Master-Papers/07-The-Diet.html'>The Electro-Nutrient Protocol</a></li><li><a href='../01-Master-Papers/06-The-Fusion.html'>The Energy Solution</a></li><li><a href='../01-Master-Papers/08-Bibliography.html'>The Logic Bridge: Verified Science</a></li><li><a href='../01-Master-Papers/02-The-Compass.html'>The Metabolic Compass</a></li><li><a href='../01-Master-Papers/02-Volume-2-The-Archetypes.html'>The Osteo</a></li><li><a href='../01-Master-Papers/01-The-Merger.html'>The Placozoan-Algal Merger</a></li><li><a href='../01-Master-Papers/03-Volume-3-The-Pathology.html'>Viral3</a></li><li><a href='../01-Master-Papers/04-Volume-4-The-Origin.html'>Z4_Oxidative_Stress_CISS_Spin</a></li><br><li><strong>APPENDICES</strong></li><li><a href='../00-ARCHIVE/1.html'>1</a></li><li><a href='../00-ARCHIVE/ABio-cancer.html'>A Bio-cancer</a></li><li><a href='../00-ARCHIVE/A1_The_Cranial_Dynamo.html'>A1_The_Cranial_Dynamo</a></li><li><a href='../00-ARCHIVE/A2_Bone_as_Piezoelectric_Shield1.html'>A2_Bone_as_Piezoelectric_Shield (1)</a></li><li><a href='../00-ARCHIVE/A3_Charge_Asymmetry1.html'>A3_Charge_Asymmetry (1)</a></li><li><a href='../00-ARCHIVE/A4_Fascia_Conductive_Network.html'>A4_Fascia_Conductive_Network</a></li><li><a href='../00-ARCHIVE/AGINGASLOSSOFSEPARATION1.html'>AGING AS LOSS OF SEPARATION 1</a></li><li><a href='../00-ARCHIVE/ALL_FILES_LIST.html'>ALL_FILES_LIST.txt</a></li><li><a href='../00-ARCHIVE/ALL_RAW_CONTENT_MASTER_FILE.html'>ALL_RAW_CONTENT_MASTER_FILE.txt</a></li><li><a href='../00-ARCHIVE/ALL_RAW_CONTENT_MASTER_FILE_FULL.html'>ALL_RAW_CONTENT_MASTER_FILE_FULL.txt</a></li><li><a href='../00-ARCHIVE/ASFDAS.html'>ASFDAS</a></li><li><a href='../00-ARCHIVE/ATOPICDERMATITIS.html'>ATOPIC DERMATITIS</a></li><li><a href='../00-ARCHIVE/ATOPICDERMATITIS1.html'>ATOPIC DERMATITIS1</a></li><li><a href='../00-ARCHIVE/Abstract.html'>Abstract</a></li><li><a href='../00-ARCHIVE/AnElectrochemicalHypothesisforCancer.html'>An Electrochemical Hypothesis for Cancer</a></li><li><a href='../00-ARCHIVE/B2_Neurotransmitter_Sequence.html'>B2_Neurotransmitter_Sequence</a></li><li><a href='../00-ARCHIVE/B3_Placozoan_Split.html'>B3_Placozoan_Split</a></li><li><a href='../00-ARCHIVE/B4_PLP_Bottleneck.html'>B4_PLP_Bottleneck</a></li><li><a href='../00-ARCHIVE/BREASTCANCER.html'>BREAST CANCER</a></li><li><a href='../00-ARCHIVE/01.03-blood-type-hardware.html'>Blood Types as Metabolic Hardware</a></li><li><a href='../00-ARCHIVE/C1_Metabolic_Origins_Sexlessness.html'>C1_Metabolic_Origins_Sexlessness</a></li><li><a href='../00-ARCHIVE/C4_Neurochemistry_Hubris.html'>C4_Neurochemistry_Hubris</a></li><li><a href='../00-ARCHIVE/C5_ADHD_Dopamine_Failure1.html'>C5_ADHD_Dopamine_Failure (1)</a></li><li><a href='../00-ARCHIVE/CANCERDRAFT2.html'>CANCER DRAFT 2</a></li><li><a href='../00-ARCHIVE/Cancerdraft1.html'>Cancer draft 1</a></li><li><a href='../00-ARCHIVE/Cellgrowthgeneral.html'>Cell growth general</a></li><li><a href='../00-ARCHIVE/Choline.html'>Choline</a></li><li><a href='../00-ARCHIVE/Choline-final.html'>Choline - final</a></li><li><a href='../00-ARCHIVE/Choline1.html'>Choline1</a></li><li><a href='../00-ARCHIVE/Choline2.html'>Choline2</a></li><li><a href='../00-ARCHIVE/Choline3.html'>Choline3</a></li><li><a href='../00-ARCHIVE/Choline5.html'>Choline5</a></li><li><a href='../00-ARCHIVE/Choline6.html'>Choline6</a></li><li><a href='../00-ARCHIVE/ChronicKidneyDiseaseasaFailureofGlomerularOscillatoryHemodynamics.html'>Chronic Kidney Disease as a Failure of Glomerular </a></li><li><a href='../00-ARCHIVE/CoverLette2.html'>Cover Lette2</a></li><li><a href='../00-ARCHIVE/Coverletter.html'>Cover letter</a></li><li><a href='../00-ARCHIVE/D1_Cranial_Reversal_Maneuver.html'>D1_Cranial_Reversal_Maneuver</a></li><li><a href='../00-ARCHIVE/D2_4_Phasic_Metabolic_Diet.html'>D2_4_Phasic_Metabolic_Diet</a></li><li><a href='../00-ARCHIVE/D4_Grounding_Rod_Protocol.html'>D4_Grounding_Rod_Protocol</a></li><li><a href='../00-ARCHIVE/DIMENSIONALBIOPHYSICS-TITLEPAGE.html'>DIMENSIONAL BIOPHYSICS - TITLE PAGE</a></li><li><a href='../00-ARCHIVE/DOCI.html'>DOCI</a></li><li><a href='../00-ARCHIVE/DearEdito1.html'>Dear Edito1</a></li><li><a href='../00-ARCHIVE/DearEditor.html'>Dear Editor</a></li><li><a href='../00-ARCHIVE/DeficientCNSpHBufferingandtheGABAergicCollapseinSchizophrenia.html'>Deficient CNS pH Buffering and the GABAergic Colla</a></li><li><a href='../00-ARCHIVE/E1_Quantum_Zeno_Enzyme_Catalysis.html'>E1_Quantum_Zeno_Enzyme_Catalysis</a></li><li><a href='../00-ARCHIVE/E2_Proton_Tunneling_DNA.html'>E2_Proton_Tunneling_DNA</a></li><li><a href='../00-ARCHIVE/E3_Tryptophan_Excitonic_Wire.html'>E3_Tryptophan_Excitonic_Wire</a></li><li><a href='../00-ARCHIVE/E4_Microtubule_Coherence_Time.html'>E4_Microtubule_Coherence_Time</a></li><li><a href='../00-ARCHIVE/E5_Iron_Sulfur_Clusters.html'>E5_Iron_Sulfur_Clusters</a></li><li><a href='../00-ARCHIVE/FULL_LIBRARY_CONTENT_DUMP.html'>FULL_LIBRARY_CONTENT_DUMP.txt</a></li><li><a href='../00-ARCHIVE/Frontalis.html'>Frontalis</a></li><li><a href='../00-ARCHIVE/H1_Phloem_Waves.html'>H1_Phloem_Waves</a></li><li><a href='../00-ARCHIVE/H2_Root_Brain_Grounding.html'>H2_Root_Brain_Grounding</a></li><li><a href='../00-ARCHIVE/H3_Soil_External_Rumen.html'>H3_Soil_External_Rumen</a></li><li><a href='../00-ARCHIVE/HUBBLETENSION.html'>HUBBLE TENSION</a></li><li><a href='../00-ARCHIVE/Highlight2.html'>Highlight2</a></li><li><a href='../00-ARCHIVE/Highlights.html'>Highlights</a></li><li><a href='../00-ARCHIVE/I1_Depression_Membrane_Headroom.html'>I1_Depression_Membrane_Headroom</a></li><li><a href='../00-ARCHIVE/I2_Anxiety_High_Gain_Noise.html'>I2_Anxiety_High_Gain_Noise</a></li><li><a href='../00-ARCHIVE/I3_Bipolar_Phase_Lock.html'>I3_Bipolar_Phase_Lock</a></li><li><a href='../00-ARCHIVE/Itstripsawaythemedicalapplications.html'>It strips away the medical applications</a></li><li><a href='../00-ARCHIVE/J3_Retrotransposon_Viral_Wake.html'>J3_Retrotransposon_Viral_Wake</a></li><li><a href='../00-ARCHIVE/J5_CRISPR_Target_Shielding.html'>J5_CRISPR_Target_Shielding</a></li><li><a href='../00-ARCHIVE/JOURNALOFEVOLUTIONARYBIOLOGY.html'>JOURNAL OF EVOLUTIONARY BIOLOGY</a></li><li><a href='../00-ARCHIVE/Journal_of_Evolutionary_Biology_Submission.html'>Journal_of_Evolutionary_Biology_Submission</a></li><li><a href='../00-ARCHIVE/LONGCOVID.html'>LONG COVID</a></li><li><a href='../00-ARCHIVE/Lifewasfirstcreatedthroughastruggleagainstauniversalforceinourunivers1.html'>Life was first created through a struggle against </a></li><li><a href='../00-ARCHIVE/Lifewasfirstcreatedthroughastruggleagainstauniversalforceinouruniverse-2.html'>Life was first created through a struggle against </a></li><li><a href='../00-ARCHIVE/MIGRAINE.html'>MIGRAINE</a></li><li><a href='../00-ARCHIVE/MelanomaasaFailureofBio.html'>Melanoma as a Failure of Bio</a></li><li><a href='../00-ARCHIVE/OlfactoryHallucinationsasBiomarkersofNeuralAutophagy.html'>Olfactory Hallucinations as Biomarkers of Neural A</a></li><li><a href='../00-ARCHIVE/OrthogonalFieldModulationofNitrogenaseElectronFluxANovelStrategyforEnhancedBiohydrogenProduction.html'>Orthogonal Field Modulation of Nitrogenase Electro</a></li><li><a href='../00-ARCHIVE/OsteoporosisasaChrono.html'>Osteoporosis as a Chrono</a></li><li><a href='../00-ARCHIVE/PAPER3.html'>PAPER 3</a></li><li><a href='../00-ARCHIVE/PARKINSONS.html'>PARKINSONS</a></li><li><a href='../00-ARCHIVE/PDAC.html'>PDAC</a></li><li><a href='../00-ARCHIVE/Paper_1_Container_Principle_Scientific.html'>Paper_1_Container_Principle_Scientific.txt</a></li><li><a href='../00-ARCHIVE/Paper_1_Scientific_Protocol_Only.html'>Paper_1_Scientific_Protocol_Only</a></li><li><a href='../00-ARCHIVE/Paper_2_The_Three_Solutions.html'>Paper_2_The_Three_Solutions</a></li><li><a href='../00-ARCHIVE/Paper_3_Atmospheric_Interface_Protocol.html'>Paper_3_Atmospheric_Interface_Protocol</a></li><li><a href='../00-ARCHIVE/Paper_3_The_Invisible_Hand.html'>Paper_3_The_Invisible_Hand</a></li><li><a href='../00-ARCHIVE/Paper_4_The_Tearing_Mode_Solved.html'>Paper_4_The_Tearing_Mode_Solved</a></li><li><a href='../00-ARCHIVE/Placozoan.html'>Placozoan</a></li><li><a href='../00-ARCHIVE/QUANTUMTELEPORTATIO2.html'>QUANTUM TELEPORTATIO2</a></li><li><a href='../00-ARCHIVE/QUANTUMTELEPORTATION.html'>QUANTUM TELEPORTATION</a></li><li><a href='../00-ARCHIVE/QUANTUMTELEPORTATION1.html'>QUANTUM TELEPORTATION1</a></li><li><a href='../00-ARCHIVE/SCHIZOPHRENIA4.html'>SCHIZOPHRENIA 4</a></li><li><a href='../00-ARCHIVE/Schizophreniaasanα2.html'>Schizophrenia as an α2</a></li><li><a href='../00-ARCHIVE/StemcellforOrganProduction.html'>Stem cell for Organ Production</a></li><li><a href='../00-ARCHIVE/SuddenInfantDeathSyndromeasaTransientFailureofChrono.html'>Sudden Infant Death Syndrome as a Transient Failur</a></li><li><a href='../00-ARCHIVE/SuicideasaThermodynamicFailureofthe.html'>Suicide as a Thermodynamic Failure of the</a></li><li><a href='../00-ARCHIVE/SystemicLupusErythematosusasaFailureofLymphaticClearance.html'>Systemic Lupus Erythematosus as a Failure of Lymph</a></li><li><a href='../00-ARCHIVE/THEELECTROCHEMICALORIGINSOFLIF1.html'>THE ELECTROCHEMICAL ORIGINS OF LIF1</a></li><li><a href='../00-ARCHIVE/THEELECTROCHEMICALORIGINSOFLIFE.html'>THE ELECTROCHEMICAL ORIGINS OF LIFE</a></li><li><a href='../00-ARCHIVE/THEORTHOGONALREDOXSWITCH.html'>THE ORTHOGONAL REDOX SWITCH</a></li><li><a href='../00-ARCHIVE/THEVIBRATIONALGATINGOFTHERHIZOSPHERE.html'>THE VIBRATIONAL GATING OF THE RHIZOSPHERE</a></li><li><a href='../00-ARCHIVE/4.01-the-sexual-metabolism.html'>Testosterone and Estrogen: The Retaliation Pair</a></li><li><a href='../00-ARCHIVE/TheAcidShield.html'>The Acid Shield</a></li><li><a href='../00-ARCHIVE/TheAcidShield1.html'>The Acid Shield(1)</a></li><li><a href='../00-ARCHIVE/TheAntioxidantParadox.html'>The Antioxidant Paradox</a></li><li><a href='../00-ARCHIVE/TheBreastasanEntropyTrap.html'>The Breast as an Entropy Trap</a></li><li><a href='../00-ARCHIVE/TheBreastasanEntropyTrap1.html'>The Breast as an Entropy Trap1</a></li><li><a href='../00-ARCHIVE/TheChrono.html'>The Chrono</a></li><li><a href='../00-ARCHIVE/TheCollapseoftheClimbingCurrent-PARKINSONS.html'>The Collapse of the Climbing Current - PARKINSON'S</a></li><li><a href='../00-ARCHIVE/TheCranialArc.html'>The Cranial Arc</a></li><li><a href='../00-ARCHIVE/TheGABAergicShieldLoss.html'>The GABAergic Shield Loss</a></li><li><a href='../00-ARCHIVE/TheGeometricDescentandtheMetabolicAscen1.html'>The Geometric Descent and the Metabolic Ascen1</a></li><li><a href='../00-ARCHIVE/TheGeometricDescentandtheMetabolicAscent.html'>The Geometric Descent and the Metabolic Ascent</a></li><li><a href='../00-ARCHIVE/TheGlutamatergicOverloadHypothesisofAmyotrophicLateralSclerosi1.html'>The Glutamatergic Overload Hypothesis of Amyotroph</a></li><li><a href='../00-ARCHIVE/TheGlutamatergicOverloadHypothesisofAmyotrophicLateralSclerosis.html'>The Glutamatergic Overload Hypothesis of Amyotroph</a></li><li><a href='../00-ARCHIVE/TheInternalizedStressPhenotypeABO.html'>The Internalized Stress Phenotype ABO</a></li><li><a href='../00-ARCHIVE/TheLactate-GABAShuttleHypothesis.html'>The Lactate-GABA Shuttle Hypothesis</a></li><li><a href='../00-ARCHIVE/02.01-mechanism-of-collapse.html'>The Mechanism of Dimensional Collapse</a></li><li><a href='../00-ARCHIVE/TheNeuralAr1.html'>The Neural Ar1</a></li><li><a href='../00-ARCHIVE/TheNeuralArc.html'>The Neural Arc</a></li><li><a href='../00-ARCHIVE/01.02-dimensional-evolution.html.html'>The Neurotransmitter Evolutionary Sequence</a></li><li><a href='../00-ARCHIVE/TheOsteo.html'>The Osteo</a></li><li><a href='../00-ARCHIVE/TheOsteoporosis.html'>The Osteoporosis</a></li><li><a href='../00-ARCHIVE/TheRazo1.html'>The Razo1</a></li><li><a href='../00-ARCHIVE/TheRazor.html'>The Razor</a></li><li><a href='../00-ARCHIVE/TheRazor1.html'>The Razor(1)</a></li><li><a href='../00-ARCHIVE/01.01-thermodynamic-origins.html.html'>The Thermodynamic Origin of Life</a></li><li><a href='../00-ARCHIVE/TheTriadofCollapse-ALS.html'>The Triad of Collapse -ALS</a></li><li><a href='../00-ARCHIVE/The-ALS_Amyotrophic_Lateral_Sclerosis_Scientific_Protocol.html'>The-ALS_(Amyotrophic_Lateral_Sclerosis)_Scientific</a></li><li><a href='../00-ARCHIVE/The-Acne_Vulgaris_Triad.html'>The-Acne_Vulgaris_Triad</a></li><li><a href='../00-ARCHIVE/The-Adrenal_Burnout_HPA_Axis_Dysregulation_Scientific_Protocol.html'>The-Adrenal_Burnout_(HPA_Axis_Dysregulation)_Scien</a></li><li><a href='../00-ARCHIVE/The-Alzheimers_Disease_Type_3_Diabetes_Scientific_Protocol.html'>The-Alzheimer's_Disease_(Type_3_Diabetes)_Scientif</a></li><li><a href='../00-ARCHIVE/The-Androgenetic_Alopecia_Male_Pattern_Baldness_Scientific_Protocol.html'>The-Androgenetic_Alopecia_(Male_Pattern_Baldness)_</a></li><li><a href='../00-ARCHIVE/The-Asthma_Scientific_Protocol.html'>The-Asthma_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Autism_Spectrum_Gut-Brain_Scientific_Protocol.html'>The-Autism_Spectrum_(Gut-Brain)_Scientific_Protoco</a></li><li><a href='../00-ARCHIVE/The-Bipolar_Disorder_Scientific_Protocol.html'>The-Bipolar_Disorder_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Brain_Zaps_SSRI_Withdrawal_Scientific_Protocol.html'>The-Brain_Zaps_(SSRI_Withdrawal)_Scientific_Protoc</a></li><li><a href='../00-ARCHIVE/The-Breast_Cancer_Prevention_Scientific_Protocol.html'>The-Breast_Cancer_(Prevention)_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Bruxism_Sleep_Grinding_Scientific_Protocol.html'>The-Bruxism_(Sleep_Grinding)_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Burning_Mouth_Syndrome_Scientific_Protocol.html'>The-Burning_Mouth_Syndrome_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Cancer_General_Metabolic_Support_Scientific_Protocol.html'>The-Cancer_(General_Metabolic_Support)_Scientific_</a></li><li><a href='../00-ARCHIVE/The-Chronic_Fatigue_Syndrome_MECFS_Scientific_Protocol.html'>The-Chronic_Fatigue_Syndrome_(MECFS)_Scientific_Pr</a></li><li><a href='../00-ARCHIVE/The-Cold_Urticaria_Allergy_to_Cold_Scientific_Protocol.html'>The-Cold_Urticaria_(Allergy_to_Cold)_Scientific_Pr</a></li><li><a href='../00-ARCHIVE/The-Colon_Cancer_Prevention_Scientific_Protocol.html'>The-Colon_Cancer_(Prevention)_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Costochondritis_Chest_Wall_Pain_Scientific_Protocol.html'>The-Costochondritis_(Chest_Wall_Pain)_Scientific_P</a></li><li><a href='../00-ARCHIVE/The-Crohns_Disease_Scientific_Protocol.html'>The-Crohn's_Disease_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Dry_Eye_Syndrome_Scientific_Protocol.html'>The-Dry_Eye_Syndrome_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Eczema_Atopic_Dermatitis_Scientific_Protocol.html'>The-Eczema_(Atopic_Dermatitis)_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Endometriosis_Triad.html'>The-Endometriosis_Triad</a></li><li><a href='../00-ARCHIVE/The-Erectile_Dysfunction_Triad.html'>The-Erectile_Dysfunction_Triad</a></li><li><a href='../00-ARCHIVE/The-Fibromyalgia_Scientific_Protocol.html'>The-Fibromyalgia_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Fibromyalgia_Triad.html'>The-Fibromyalgia_Triad</a></li><li><a href='../00-ARCHIVE/The-Frozen_Shoulder_Adhesive_Capsulitis_Scientific_Protocol.html'>The-Frozen_Shoulder_(Adhesive_Capsulitis)_Scientif</a></li><li><a href='../00-ARCHIVE/The-Geographic_Tongue_Scientific_Protocol.html'>The-Geographic_Tongue_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Gingivitis_Scientific_Protocol.html'>The-Gingivitis_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Glaucoma_Low_Tension_Triad.html'>The-Glaucoma_(Low_Tension)_Triad</a></li><li><a href='../00-ARCHIVE/The-Glioblastoma_GBM_Scientific_Protocol.html'>The-Glioblastoma_(GBM)_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Gout_Triad.html'>The-Gout_Triad</a></li><li><a href='../00-ARCHIVE/The-Graves_Disease_Scientific_Protocol.html'>The-Graves'_Disease_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-HIV_Retrovirus_Scientific_Protocol.html'>The-HIV_(Retrovirus)_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Hangover_Alcohol_Toxicity_Scientific_Protocol.html'>The-Hangover_(Alcohol_Toxicity)_Scientific_Protoco</a></li><li><a href='../00-ARCHIVE/The-Hashimotos_Thyroiditis_Scientific_Protocol.html'>The-Hashimoto's_Thyroiditis_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Herniated_Disc_Scientific_Protocol.html'>The-Herniated_Disc_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Histamine_Intolerance_HIT_Scientific_Protocol.html'>The-Histamine_Intolerance_(HIT)_Scientific_Protoco</a></li><li><a href='../00-ARCHIVE/The-Hypothyroidism_Hashimotos_Triad.html'>The-Hypothyroidism_(Hashimoto's)_Triad</a></li><li><a href='../00-ARCHIVE/The-Insomnia_Triad.html'>The-Insomnia_Triad</a></li><li><a href='../00-ARCHIVE/The-Interstitial_Cystitis_Painful_Bladder_Scientific_Protocol.html'>The-Interstitial_Cystitis_(Painful_Bladder)_Scient</a></li><li><a href='../00-ARCHIVE/The-Irritable_Bowel_Syndrome_IBS_Scientific_Protocol.html'>The-Irritable_Bowel_Syndrome_(IBS)_Scientific_Prot</a></li><li><a href='../00-ARCHIVE/The-Jet_Lag_Scientific_Protocol.html'>The-Jet_Lag_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Kyphosis_Hunchback_Scientific_Protocol.html'>The-Kyphosis_(Hunchback)_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Laryngopharyngeal_Reflux_Silent_Reflux_Scientific_Protocol.html'>The-Laryngopharyngeal_Reflux_(Silent_Reflux)_Scien</a></li><li><a href='../00-ARCHIVE/The-Long_COVID_PASC_Scientific_Protocol.html'>The-Long_COVID_(PASC)_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Low_Libido_Hypoactive_Sexual_Desire_Scientific_Protocol.html'>The-Low_Libido_(Hypoactive_Sexual_Desire)_Scientif</a></li><li><a href='../00-ARCHIVE/The-Lupus_SLE_Scientific_Protocol.html'>The-Lupus_(SLE)_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Lyme_Disease_Chronic_Scientific_Protocol.html'>The-Lyme_Disease_(Chronic)_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Macular_Degeneration_AMD_Triad.html'>The-Macular_Degeneration_(AMD)_Triad</a></li><li><a href='../00-ARCHIVE/The-Malaria_Plasmodium_Scientific_Protocol.html'>The-Malaria_(Plasmodium)_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Misophonia_Sound_Rage_Scientific_Protocol.html'>The-Misophonia_(Sound_Rage)_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Motion_Sickness_Scientific_Protocol.html'>The-Motion_Sickness_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Mouth_Breathing_Chronic_Scientific_Protocol.html'>The-Mouth_Breathing_(Chronic)_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Multiple_Sclerosis_MS_Scientific_Protocol.html'>The-Multiple_Sclerosis_(MS)_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Multiple_Sclerosis_Triad.html'>The-Multiple_Sclerosis_Triad</a></li><li><a href='../00-ARCHIVE/The-Myopia_Nearsightedness_Scientific_Protocol.html'>The-Myopia_(Nearsightedness)_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Night_Sweats_Scientific_Protocol.html'>The-Night_Sweats_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-POTS_Postural_Orthostatic_Tachycardia_Scientific_Protocol.html'>The-POTS_(Postural_Orthostatic_Tachycardia)_Scient</a></li><li><a href='../00-ARCHIVE/The-Parkinsons_Disease_Scientific_Protocol.html'>The-Parkinson's_Disease_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Parkinsons_Disease_Triad.html'>The-Parkinson's_Disease_Triad</a></li><li><a href='../00-ARCHIVE/The-Polycystic_Ovary_Syndrome_PCOS_Triad.html'>The-Polycystic_Ovary_Syndrome_(PCOS)_Triad</a></li><li><a href='../00-ARCHIVE/The-Prostate_Cancer_Support_Scientific_Protocol.html'>The-Prostate_Cancer_(Support)_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Psoriasis_Scientific_Protocol.html'>The-Psoriasis_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Psoriasis_Triad.html'>The-Psoriasis_Triad</a></li><li><a href='../00-ARCHIVE/The-Restless_Leg_Syndrome_RLS_Scientific_Protocol.html'>The-Restless_Leg_Syndrome_(RLS)_Scientific_Protoco</a></li><li><a href='../00-ARCHIVE/The-Rheumatoid_Arthritis_RA_Scientific_Protocol.html'>The-Rheumatoid_Arthritis_(RA)_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Schizophrenia_Metabolic_Scientific_Protocol.html'>The-Schizophrenia_(Metabolic)_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Sciatica_Scientific_Protocol.html'>The-Sciatica_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Scoliosis_Scientific_Protocol.html'>The-Scoliosis_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Sjogrens_Syndrome_Scientific_Protocol.html'>The-Sjogren's_Syndrome_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Sjogrens_Syndrome_Triad.html'>The-Sjogren's_Syndrome_Triad</a></li><li><a href='../00-ARCHIVE/The-Skin_Aging_Wrinkles_Scientific_Protocol.html'>The-Skin_Aging_(Wrinkles)_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Sleep_Apnea_Obstructive_Scientific_Protocol.html'>The-Sleep_Apnea_(Obstructive)_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Sleep_Apnea_Obstructive_Triad.html'>The-Sleep_Apnea_(Obstructive)_Triad</a></li><li><a href='../00-ARCHIVE/The-Small_Intestinal_Bacterial_Overgrowth_SIBO_Scientific_Protocol.html'>The-Small_Intestinal_Bacterial_Overgrowth_(SIBO)_S</a></li><li><a href='../00-ARCHIVE/The-Snoring_Scientific_Protocol.html'>The-Snoring_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Tinnitus_Scientific_Protocol.html'>The-Tinnitus_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Tinnitus_Triad.html'>The-Tinnitus_Triad</a></li><li><a href='../00-ARCHIVE/The-Tuberculosis_Mycobacterium_Scientific_Protocol.html'>The-Tuberculosis_(Mycobacterium)_Scientific_Protoc</a></li><li><a href='../00-ARCHIVE/The-Tumor_Lysis_Cancer_Scientific_Protocol.html'>The-Tumor_Lysis_(Cancer)_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Ulcerative_Colitis_Scientific_Protocol.html'>The-Ulcerative_Colitis_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Ulcerative_Colitis_Triad.html'>The-Ulcerative_Colitis_Triad</a></li><li><a href='../00-ARCHIVE/The-Vertigo_BPPV_Scientific_Protocol.html'>The-Vertigo_(BPPV)_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Vertigo_BPPV_Menieres_Triad.html'>The-Vertigo_(BPPV_Meniere's)_Triad</a></li><li><a href='../00-ARCHIVE/The-Visual_Snow_Syndrome_Scientific_Protocol.html'>The-Visual_Snow_Syndrome_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/The-Zika_Virus_Scientific_Protocol.html'>The-Zika_Virus_Scientific_Protocol</a></li><li><a href='../00-ARCHIVE/Title.html'>Title</a></li><li><a href='../00-ARCHIVE/Title1.html'>Title1</a></li><li><a href='../00-ARCHIVE/Title2.html'>Title2</a></li><li><a href='../00-ARCHIVE/TotheEditor.html'>To the Editor</a></li><li><a href='../00-ARCHIVE/VertexOverloa1.html'>Vertex Overloa1</a></li><li><a href='../00-ARCHIVE/VertexOverload.html'>Vertex Overload</a></li><li><a href='../00-ARCHIVE/Viral.html'>Viral</a></li><li><a href='../00-ARCHIVE/Viral1.html'>Viral1</a></li><li><a href='../00-ARCHIVE/Viral2.html'>Viral2</a></li><li><a href='../00-ARCHIVE/Viral3.html'>Viral3</a></li><li><a href='../communication/2025-12-07-intro.html'>Why I Created This Framework</a></li><li><a href='../00-ARCHIVE/Y1_AI_Server_Cooling_Fever.html'>Y1_AI_Server_Cooling_Fever</a></li><li><a href='../00-ARCHIVE/Y2_Battery_Degradation_Sclerosis.html'>Y2_Battery_Degradation_Sclerosis</a></li><li><a href='../00-ARCHIVE/Y3_Desalination_Burnout_Osmosis.html'>Y3_Desalination_Burnout_Osmosis</a></li><li><a href='../00-ARCHIVE/Z4_Oxidative_Stress_CISS_Spin.html'>Z4_Oxidative_Stress_CISS_Spin</a></li><li><a href='../00-ARCHIVE/agingpart2.html'>aging part2</a></li><li><a href='../00-ARCHIVE/alzheimers3.html'>alzheimers3</a></li><li><a href='../00-ARCHIVE/asdfa.html'>asdfa</a></li><li><a href='../00-ARCHIVE/bioenergeticsandmetabolism.html'>bioenergetics and metabolism</a></li><li><a href='../00-ARCHIVE/breastcancerdraft.html'>breast cancer draft</a></li><li><a href='../00-ARCHIVE/cancerBiophysics.html'>cancer Biophysics</a></li><li><a href='../00-ARCHIVE/cancerandmetabolism.html'>cancer and metabolism</a></li><li><a href='../00-ARCHIVE/choline4.html'>choline4</a></li><li><a href='../00-ARCHIVE/claude2.html'>claude2</a></li><li><a href='../00-ARCHIVE/climatechange4.html'>climate change 4</a></li><li><a href='../00-ARCHIVE/gabaergicshieldloss2.html'>gabaergic shield loss 2</a></li><li><a href='../00-ARCHIVE/glaucoma.html'>glaucoma</a></li><li><a href='../00-ARCHIVE/gppcover.html'>gpp cover</a></li><li><a href='../00-ARCHIVE/highlight4.html'>highlight4</a></li><li><a href='../00-ARCHIVE/melanoma.html'>melanoma</a></li><li><a href='../00-ARCHIVE/quantumcomputing.html'>quantum computing</a></li><li><a href='../00-ARCHIVE/quantumcomputingnotes.html'>quantum computing notes</a></li></ul></div>
            <div class="main-content">
                <h1>Choline3</h1>
<p>Choline-SAM-GABA Dysregulation as a Unified Metabolic Framework Linking </p>
<p>Cancer and Alzheimer's Disease Through Mirror Pathologies</p>
<p>ABSTRACT</p>
<p>Cancer and Alzheimer's disease (AD) demonstrate a robust inverse epidemiological </p>
<p>relationship—cancer survivors show 33% reduced AD risk while AD patients exhibit </p>
<p>69% lower cancer incidence. We propose that both diseases arise from a shared </p>
<p>metabolic vulnerability rooted in simultaneous deficiency of ionotropic GABA_A </p>
<p>and metabotropic GABA_B receptor systems, creating permissive conditions for </p>
<p>either uncontrolled proliferation or autoimmune-like neurodegeneration. Central </p>
<p>to this framework is the energetic equivalence between dual-GABA system </p>
<p>dysfunction and impaired choline biosynthesis via S-adenosylmethionine (SAM)-</p>
<p>dependent phosphatidylethanolamine methylation. Both processes involve internal </p>
<p>electron redistribution without net redox changes, creating metabolic constraint: </p>
<p>cells cannot simultaneously maintain robust dual-GABA function and adequate </p>
<p>SAM-dependent choline synthesis under resource limitation. This constraint leads </p>
<p>to alpha-ketoglutarate dysregulation—accumulation disrupts alpha-ketoglutarate-</p>
<p>dependent dioxygenases controlling DNA/histone methylation, while circadian </p>
<p>disruption creates temporal vulnerability windows. Cancer emerges when </p>
<p>proliferative signaling proceeds without GABAergic inhibitory control; AD emerges </p>
<p>when inflammatory responses cannot discharge externally and redirect as </p>
<p>neurodegeneration. The framework explains the inverse relationship through mutual </p>
<p>exclusivity: once one pathway activates, it consumes metabolic resources and </p>
<p>actively inhibits the alternative. We present testable predictions and unified </p>
<p>therapeutic strategies targeting choline-SAM metabolism, GABAergic restoration, </p>
<p>and chronotherapeutic optimization.</p>
<p>KEYWORDS: cancer metabolism, Alzheimer's disease, choline biosynthesis, GABA </p>
<p>receptors, S-adenosylmethionine, inverse epidemiology</p>
<ol>
<li>INTRODUCTION</li>
</ol>
<p>The Inverse Epidemiological Paradox and Shared Metabolic Abnormalities</p>
<p>Multiple independent epidemiological studies document a striking inverse </p>
<p>relationship between cancer and Alzheimer's disease. Driver et al. reported that </p>
<p>cancer survivors demonstrated 33% decreased AD risk while AD patients showed 69% </p>
<p>lower cancer hospitalization risk (1). Meta-analyses confirm AD patients show 47% </p>
<p>reduced overall cancer risk (RR: 0.53) while cancer patients demonstrate 39% </p>
<p>reduced AD risk (RR: 0.61) (2). Autopsy studies validate this relationship even </p>
<p>when controlling for diagnostic bias (3), suggesting genuine biological opposition </p>
<p>rather than surveillance artifacts.</p>
<p>Despite their inverse occurrence, both diseases share striking metabolic </p>
<p>abnormalities. Altered choline metabolism characterizes cancer—the "cholinic </p>
<p>phenotype" of elevated phosphocholine observable across all tested cancer types </p>
<p>reflects upregulated choline kinase and massive choline flux (4,5). AD demonstrates </p>
<p>equally profound cholinergic abnormalities, with marked choline acetyltransferase </p>
<p>decline and preferential basal forebrain cholinergic neuron degeneration (6,7). </p>
<p>Both diseases show severe circadian disruption—shift work substantially elevates </p>
<p>cancer risk (8,9) while AD demonstrates sundowning and sleep-wake cycle reversal </p>
<p>(10). Alpha-ketoglutarate dysregulation links both: AD shows 50-75% KGDHC reduction </p>
<p>(11,12), while cancer demonstrates profound α-KG disturbances through IDH mutations </p>
<p>and altered TCA flux (13,14).</p>
<p>These parallel metabolic abnormalities in inversely-occurring diseases suggest a </p>
<p>paradox: if both conditions share common metabolic vulnerabilities, why do they </p>
<p>show inverse epidemiology? We hypothesize that this reflects mutually exclusive </p>
<p>failure modes of shared underlying metabolic constraint.</p>
<ol>
<li>THE HYPOTHESIS: ENERGETIC EQUIVALENCE AND METABOLIC CONSTRAINT</li>
</ol>
<p>2.1 The Central Proposition: Energetic Equivalence</p>
<p>We propose that simultaneous deficiency in both ionotropic GABA_A and metabotropic </p>
<p>GABA_B receptor systems is energetically equivalent to impaired choline biosynthesis </p>
<p>via SAM-dependent pathways. This equivalence creates a fundamental metabolic </p>
<p>constraint that predisposes to either cancer or AD depending on which stress-</p>
<p>response pathways subsequently activate.</p>
<p>The mechanistic basis involves energetic signatures. SAM-dependent choline </p>
<p>synthesis—sequential methylation of phosphatidylethanolamine to phosphatidylcholine </p>
<p>via PEMT—consumes three SAM molecules per choline through pure methylation reactions </p>
<p>without external electron exchange (15,16). In hepatocytes, approximately 30% of </p>
<p>phosphatidylcholine synthesis proceeds through PEMT (17). Critically, each </p>
<p>methylation involves only internal electron redistribution without net redox </p>
<p>changes—no NAD+/NADH interconversion, no FAD/FADH2 cycling, no oxygen utilization </p>
<p>(18).</p>
<p>GABA receptor-mediated regulatory processes share this energetic characteristic. </p>
<p>GABA_A receptor activation produces chloride flux—pure ionic redistribution without </p>
<p>redox chemistry (19). GABA_B receptor signaling modulates enzyme activities through </p>
<p>G-protein-mediated conformational changes and phosphorylation cascades, again </p>
<p>involving charge redistribution rather than oxidation-reduction (20,21). The </p>
<p>coordinated regulation of GABA synthesis, release, and metabolic integration </p>
<p>operates through electrochemical gradients rather than redox reactions (22).</p>
<p>This energetic equivalence creates metabolic constraint: our hypothesis predicts </p>
<p>that cells cannot simultaneously maintain robust dual-GABA receptor function and </p>
<p>adequate SAM-dependent choline synthesis when metabolic resources become limiting. </p>
<p>Both processes compete for cellular energy allocation toward non-redox regulatory </p>
<p>mechanisms. When energy must be redirected toward oxidative metabolism (TCA cycle, </p>
<p>oxidative phosphorylation), processes operating through internal electron </p>
<p>redistribution become compromised.</p>
<p>2.2 Alpha-Ketoglutarate Dysregulation as the Metabolic Consequence</p>
<p>The GABA shunt—an alternative TCA cycle pathway bypassing KGDHC—involves glutamate </p>
<p>decarboxylation to GABA followed by GABA transamination with α-ketoglutarate, </p>
<p>producing succinate semialdehyde and regenerating glutamate (23,24). We hypothesize </p>
<p>that functional dual-GABA receptor systems regulate this metabolic process, thereby </p>
<p>influencing α-KG homeostasis. Deficiency in dual-GABA receptor function would </p>
<p>disrupt this regulation through: altered glutamate/GABA balance affecting GABA-T </p>
<p>substrate availability; impaired coordination between GABA synthesis and catabolism; </p>
<p>and loss of GABA receptor-mediated metabolic signaling that normally adjusts enzyme </p>
<p>activities to metabolic demands.</p>
<p>If this hypothesis is correct, dual-GABA deficiency would create conditions </p>
<p>permitting α-KG accumulation—not through simple failure to "consume" α-KG but </p>
<p>through loss of coordinated metabolic regulation. This prediction aligns with </p>
<p>observed α-KG dysregulation in both diseases: marked KGDHC deficiency in AD (11,12) </p>
<p>and α-KG perturbations in cancer through IDH mutations producing 2-hydroxyglutarate </p>
<p>(13,14).</p>
<p>Accumulated α-KG would disrupt α-KG-dependent dioxygenases controlling DNA and </p>
<p>histone methylation—TET enzymes and JmjC-domain demethylases (25,26). The balance </p>
<p>between SAM-dependent methylation (which we hypothesize is impaired due to energetic </p>
<p>equivalence with dual-GABA deficiency) and α-KG-dependent demethylation (which we </p>
<p>propose becomes hyperactive due to α-KG accumulation) determines epigenetic </p>
<p>landscapes. This framework offers a potential explanation for the paradoxical </p>
<p>methylation patterns in both diseases: cancer shows global DNA hypomethylation with </p>
<p>regional CpG island hypermethylation (27), while AD demonstrates altered histone </p>
<p>methylation affecting tau processing (28).</p>
<p>2.3 Circadian Vulnerability and "Darkness Stress"</p>
<p>Both SAM synthesis and GABA synthesis show circadian oscillation (29,30). </p>
<p>Metabotropic GABA_B receptors contribute to circadian metabolic entrainment through </p>
<p>sustained G-protein signaling modulating cAMP and CREB phosphorylation, thereby </p>
<p>affecting circadian gene expression (31). The suprachiasmatic nucleus shows dense </p>
<p>GABAergic innervation with GABA mediating communication between SCN neurons (32).</p>
<p>We hypothesize that GABA_B deficiency creates "darkness stress"—nocturnal metabolic </p>
<p>dysregulation occurring when compensatory mechanisms functioning during daylight fail </p>
<p>during dark periods. This prediction aligns with observed circadian disruption in </p>
<p>both diseases: shift work substantially elevates cancer risk (8,9), while AD </p>
<p>demonstrates sundowning and sleep-wake cycle abnormalities (10). Melatonin—the </p>
<p>primary circadian hormone—shows reduced production in both conditions (33,34).</p>
<p>The convergence of α-KG dysregulation ("cold stress") and circadian dysregulation </p>
<p>("darkness stress") during nighttime would create maximum vulnerability windows. DNA </p>
<p>repair shows circadian oscillation with efficiency peaking mid-day and reaching </p>
<p>nadir at night (35). If our hypothesis is correct, dual-GABA deficiency would </p>
<p>disrupt these protective oscillations, leaving cells vulnerable throughout extended </p>
<p>periods.</p>
<p>2.4 Disease-Specific Manifestations: Cancer vs. AD</p>
<p>Given shared metabolic vulnerability (dual-GABA deficiency with impaired SAM-</p>
<p>dependent choline synthesis), we hypothesize that disease-specific outcomes depend </p>
<p>on which stress-response pathways subsequently activate.</p>
<p>Cancer pathway: We propose cancer emerges when epinephrine-mediated proliferative </p>
<p>stress responses proceed without GABAergic inhibitory control. Cancer cells </p>
<p>demonstrate the "cholinic phenotype"—elevated phosphocholine and upregulated choline </p>
<p>kinase—which we interpret as metabolic compensation for deficient SAM-dependent </p>
<p>choline synthesis (4,5). Upregulating the Kennedy pathway (choline phosphorylation </p>
<p>to phosphocholine) and choline scavenging provides a workaround analogous to </p>
<p>organisms developing auxotrophy for nutrients they cannot synthesize. This framework </p>
<p>predicts that cancer cells' altered choline metabolism reflects not simple increased </p>
<p>membrane demand but fundamental disruption of the SAM-GABA energetic balance.</p>
<p>AD pathway: We hypothesize AD emerges when vasopressin-mediated inflammatory </p>
<p>responses cannot discharge externally and redirect as neurodegeneration. Basal </p>
<p>forebrain cholinergic neurons show particular vulnerability, which we attribute to </p>
<p>their unique metabolic demands: continuous high-rate acetylcholine synthesis </p>
<p>requiring sustained choline availability (36,37). Under dual-GABA deficiency </p>
<p>(energetically equivalent to impaired choline synthesis capacity), these neurons </p>
<p>face a double constraint: reduced synthesis capability when demands remain highest, </p>
<p>plus impaired inhibitory regulation increasing metabolic demands through </p>
<p>hyperexcitability.</p>
<p>The failure of simple choline supplementation to modify AD progression (38) supports </p>
<p>our framework: if the fundamental problem involves impaired SAM-dependent synthesis </p>
<p>capacity rather than substrate deficiency, providing exogenous choline via the </p>
<p>Kennedy pathway offers only partial compensation while the energetic constraint </p>
<p>persists.</p>
<p>2.5 The Inverse Relationship: Mutual Exclusivity</p>
<p>We hypothesize the inverse epidemiological relationship reflects mutual exclusivity </p>
<p>at the metabolic level. Both diseases require the same underlying vulnerability </p>
<p>(dual-GABA deficiency with impaired choline synthesis), but once one pathway </p>
<p>activates and dominates, it consumes metabolic resources and actively inhibits the </p>
<p>alternative pathway.</p>
<p>This framework predicts: (1) individuals with robust dual-GABA function maintain </p>
<p>both SAM-dependent choline synthesis and proper α-KG regulation, showing reduced </p>
<p>risk for both diseases; (2) individuals with dual-GABA deficiency become vulnerable </p>
<p>to both but typically manifest only one; (3) which disease manifests depends on </p>
<p>which stress-response system activates first; (4) once activated, that pathway's </p>
<p>metabolic demands prevent the alternative pathway from activating.</p>
<p>If correct, this hypothesis offers testable predictions about genetic risk factors, </p>
<p>biomarkers indicating pre-disease vulnerability, and therapeutic interventions </p>
<p>targeting the shared metabolic constraint.</p>
<ol>
<li>EVALUATION OF THE HYPOTHESIS</li>
</ol>
<p>3.1 Supporting Evidence</p>
<p>Several lines of evidence support this framework:</p>
<p>Energetic considerations: The non-redox character of both SAM-dependent methylation </p>
<p>and certain GABA regulatory processes is biochemically established (15,18-22). That </p>
<p>processes sharing energetic signatures compete when resources become limiting </p>
<p>represents fundamental bioenergetic principle.</p>
<p>Choline metabolism patterns: The cholinic phenotype in cancer (4,5) and cholinergic </p>
<p>collapse in AD (6,7) are well-documented. Our framework offers a unifying </p>
<p>explanation: both reflect consequences of impaired SAM-dependent synthesis capacity, </p>
<p>with compensatory responses differing based on disease context.</p>
<p>Alpha-KG dysregulation: KGDHC deficiency in AD (11,12) and α-KG perturbations in </p>
<p>cancer (13,14) are among the most consistent metabolic findings in these diseases. </p>
<p>The GABA shunt's role in α-KG metabolism (23,24) provides a mechanistic link between </p>
<p>GABA dysfunction and α-KG dysregulation.</p>
<p>Circadian disruption: The profound circadian abnormalities in both diseases (8-10, </p>
<p>33,34) align with our prediction that GABA_B deficiency disrupts circadian metabolic </p>
<p>entrainment. Melatonin's therapeutic promise in both conditions (though with </p>
<p>different optimal timing) supports shared circadian vulnerability manifesting through </p>
<p>different temporal patterns.</p>
<p>GABA systems in both diseases: GABA receptor expression abnormalities have been </p>
<p>documented in both cancer (39) and AD (40), though often interpreted within disease-</p>
<p>specific frameworks rather than as manifestations of shared vulnerability.</p>
<p>Genetic susceptibility: PEMT polymorphisms affect choline synthesis capacity and </p>
<p>disease susceptibility (41,42). If our hypothesis is correct, we would predict that </p>
<p>PEMT variants interact with GABAergic system genetics to determine disease risk.</p>
<p>3.2 Challenging Evidence and Alternative Explanations</p>
<p>Several observations require careful consideration:</p>
<p>Complexity of mechanisms: Both cancer and AD involve multifactorial pathogenesis. </p>
<p>Our framework proposes a metabolic constraint creating permissiveness, not a single </p>
<p>causal mechanism. Multiple additional factors (genetic, environmental, stochastic) </p>
<p>determine whether and which disease manifests.</p>
<p>GABA shunt quantitative significance: While the GABA shunt can account for 10-40% of </p>
<p>glucose-derived TCA cycle carbon in specific brain regions (43), its quantitative </p>
<p>impact on whole-organism α-KG homeostasis requires further characterization. Our </p>
<p>hypothesis predicts regulatory importance rather than necessarily quantitative </p>
<p>dominance.</p>
<p>Specificity questions: Why would dual-GABA deficiency specifically predispose to </p>
<p>cancer and AD rather than other diseases? We hypothesize these conditions reflect </p>
<p>extreme manifestations—uncontrolled proliferation vs. progressive neurodegeneration—</p>
<p>of metabolic failure modes that may have subclinical manifestations in other </p>
<p>contexts.</p>
<p>Therapeutic paradoxes: If the diseases share underlying vulnerability, why don't </p>
<p>interventions effective in one help the other? We propose this reflects disease-</p>
<p>stage differences: early intervention targeting the shared vulnerability might </p>
<p>prevent both, while late intervention after disease-specific pathology emerges </p>
<p>requires disease-specific approaches.</p>
<p>Alternative frameworks: Other hypotheses for the inverse relationship include </p>
<p>antagonistic pleiotropy (genes beneficial for one condition harmful for the other) </p>
<p>(44), p53 activity differences (45), and PIN1 dysregulation (46). Our framework is </p>
<p>compatible with these mechanisms operating downstream or in parallel with the </p>
<p>fundamental metabolic constraint we propose.</p>
<p>3.3 Critical Assumptions Requiring Validation</p>
<p>This hypothesis makes several critical assumptions requiring experimental validation:</p>
<ol>
<li>That dual-GABA deficiency (both A and B receptor systems) creates different </li>
</ol>
<p>pathophysiology than single-receptor deficiency</p>
<ol>
<li>That the energetic equivalence between SAM-dependent processes and certain GABA </li>
</ol>
<p>regulatory functions creates actual competition under metabolic constraint</p>
<ol>
<li>That α-KG accumulation resulting from dysregulated GABA shunt function </li>
</ol>
<p>significantly impacts dioxygenase activity</p>
<ol>
<li>
<p>That circadian GABA_B function plays the regulatory role we propose</p>
</li>
<li>
<p>That stress-response pathway selection (epinephrine vs. vasopressin) determines </p>
</li>
</ol>
<p>disease outcome in vulnerable individuals</p>
<ol>
<li>TESTABLE PREDICTIONS AND THERAPEUTIC IMPLICATIONS</li>
</ol>
<p>4.1 Specific Testable Predictions</p>
<p>This framework generates several experimentally testable predictions:</p>
<ol>
<li>Genetic prediction: Individuals carrying specific combinations of PEMT variants </li>
</ol>
<p>(reducing SAM-dependent choline synthesis capacity) and GABA receptor variants </p>
<p>(reducing dual-GABA function) should show elevated risk for either cancer or AD, </p>
<p>with higher combined risk than expected from additive effects alone.</p>
<ol>
<li>Biomarker prediction: Individuals with dual-GABA deficiency should show: (a) </li>
</ol>
<p>altered SAM/SAH ratios, (b) abnormal phosphatidylcholine/phosphatidylethanolamine </p>
<p>ratios, (c) elevated α-KG levels, (d) specific circadian rhythm abnormalities, (e) </p>
<p>altered methylation patterns, detectable before overt disease.</p>
<ol>
<li>Energetic prediction: Experimental metabolic constraint (limiting substrates for </li>
</ol>
<p>SAM synthesis or ATP availability) should produce greater impairment in cells with </p>
<p>pre-existing GABA receptor deficiency than in control cells, specifically affecting </p>
<p>SAM-dependent processes.</p>
<ol>
<li>Circadian prediction: The magnitude of nighttime α-KG dysregulation should </li>
</ol>
<p>correlate with GABA_B receptor function, with deficiency producing specific patterns </p>
<p>of nocturnal metabolic abnormality.</p>
<ol>
<li>Therapeutic prediction: Interventions supporting both SAM-dependent choline </li>
</ol>
<p>synthesis (SAM or betaine supplementation) and GABAergic function (GABA_B agonists) </p>
<p>should show synergistic effects in preventing or slowing disease progression, </p>
<p>superior to either intervention alone.</p>
<ol>
<li>Inverse relationship prediction: In populations with high cancer incidence, </li>
</ol>
<p>subgroups with specific GABA receptor genotypes should show lower AD incidence, and </p>
<p>vice versa, beyond the population-level inverse relationship.</p>
<p>4.2 Therapeutic Implications</p>
<p>If this hypothesis is validated, it suggests several therapeutic strategies:</p>
<p>Primary prevention: Individuals identified through genetic or biomarker screening as </p>
<p>having dual-GABA deficiency with impaired SAM-dependent choline synthesis could </p>
<p>receive: (a) optimized choline/betaine/SAM supplementation, (b) GABAergic support </p>
<p>through lifestyle (meditation, yoga) or pharmacological approaches, (c) circadian </p>
<p>optimization, (d) stress-response modulation.</p>
<p>Secondary prevention: For individuals showing early metabolic abnormalities (elevated </p>
<p>α-KG, altered methylation patterns, circadian disruption) without overt disease: (a) </p>
<p>intensive metabolic support targeting the choline-SAM-GABA axis, (b) chronotherapeutic </p>
<p>interventions optimizing medication timing, (c) monitoring for early disease </p>
<p>manifestations enabling rapid intervention.</p>
<p>Disease modification: Even after disease onset, interventions targeting the underlying </p>
<p>metabolic constraint might slow progression: (a) combination therapies addressing </p>
<p>multiple pathway components, (b) chronotherapy optimizing timing of interventions, </p>
<p>(c) personalized approaches based on individual metabolic profiles.</p>
<p>4.3 Limitations and Future Directions</p>
<p>This hypothesis faces several limitations requiring future work:</p>
<p>The energetic equivalence concept, while biochemically grounded, requires direct </p>
<p>experimental validation demonstrating competition between SAM-dependent processes </p>
<p>and GABA regulatory functions under metabolic constraint. The quantitative </p>
<p>relationships between GABA shunt activity, α-KG accumulation, and dioxygenase </p>
<p>dysfunction need characterization. The mechanisms determining which stress-response </p>
<p>pathway (cancer vs. AD) activates in vulnerable individuals remain incompletely </p>
<p>specified.</p>
<p>Future studies should: (1) test genetic predictions through large-scale association </p>
<p>studies examining PEMT-GABA receptor interactions; (2) validate biomarker predictions </p>
<p>in prospective cohorts; (3) perform mechanistic studies in model systems testing </p>
<p>energetic competition predictions; (4) conduct clinical trials of combination </p>
<p>interventions targeting the choline-SAM-GABA axis.</p>
<ol>
<li>CONCLUSIONS</li>
</ol>
<p>We propose that the inverse relationship between cancer and Alzheimer's disease </p>
<p>reflects mutually exclusive failure modes of shared metabolic vulnerability: </p>
<p>simultaneous deficiency in dual-GABA receptor systems (both ionotropic GABA_A and </p>
<p>metabotropic GABA_B), energetically equivalent to impaired SAM-dependent choline </p>
<p>biosynthesis. This creates a metabolic constraint characterized by α-ketoglutarate </p>
<p>dysregulation and circadian disruption. Cancer emerges when proliferative signaling </p>
<p>proceeds without GABAergic inhibition; AD emerges when inflammatory responses </p>
<p>redirect as neurodegeneration. The inverse epidemiology reflects mutual exclusivity: </p>
<p>once one pathway dominates, it consumes resources preventing alternative pathway </p>
<p>activation.</p>
<p>This framework unifies disparate observations—the cholinic phenotype in cancer, </p>
<p>cholinergic collapse in AD, KGDHC deficiency in AD, IDH mutations in cancer, </p>
<p>circadian disruption in both—under a single organizing principle. It generates </p>
<p>testable predictions regarding genetics, biomarkers, and therapeutic interventions. </p>
<p>If validated, it suggests that addressing the shared metabolic vulnerability through </p>
<p>combination therapies targeting choline-SAM metabolism, GABAergic restoration, and </p>
<p>circadian optimization might prevent or slow progression of both diseases.</p>
<p>The hypothesis acknowledges substantial uncertainty and requires rigorous experimental </p>
<p>testing. However, by offering a mechanistic explanation for the robust inverse </p>
<p>epidemiological relationship and providing testable predictions, it establishes a </p>
<p>framework for future investigation into the metabolic basis of two major age-related </p>
<p>diseases.</p>
<p>Author Information</p>
<p>IL WOONG CHOI
Independent Researcher, OXFORD, UK
Email: iwchoikr@gmail.com
ORCID: 0009-0004-1292-0610</p>
<p>Funding</p>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
<p>Competing Interests</p>
<p>The author declares no competing interests.</p>
<p>Ethics Approval</p>
<p>Not applicable.</p>
<p>Data Availability</p>
<p>Not applicable - no datasets were generated or analyzed during this study.</p>
<p>Declaration of Generative AI and AI-Assisted Technologies</p>
<p>During the preparation of this work, the author used AI-assisted tools in order to assist with literature search, reference identification, hypothesis articulation, and manuscript structuring. After using these tools, the author reviewed and edited the content as needed and takes full responsibility for the content of the published article.</p>
<p>REFERENCES</p>
<ol>
<li>Driver JA, Beiser A, Au R, et al. Inverse association between cancer and </li>
</ol>
<p>Alzheimer's disease: results from the Framingham Heart Study. BMJ. 2012;344:e1442.</p>
<ol>
<li>Shi HB, Tang B, Liu YW, Wang XF, Chen GJ. Alzheimer disease and cancer risk: a </li>
</ol>
<p>meta-analysis. J Cancer Res Clin Oncol. 2015;141(3):485-494.</p>
<ol>
<li>Roe CM, Behrens MI, Xiong C, Miller JP, Morris JC. Alzheimer disease and cancer. </li>
</ol>
<p>Neurology. 2005;64(5):895-898.</p>
<ol>
<li>Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. </li>
</ol>
<p>Nat Rev Cancer. 2011;11(12):835-848.</p>
<ol>
<li>Podo F, Canevari S, Canese R, Pisanu ME, Ricci A, Iorio E. MR evaluation of </li>
</ol>
<p>response to targeted treatment in cancer cells. NMR Biomed. 2011;24(6):648-672.</p>
<ol>
<li>Bartus RT, Dean RL 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric </li>
</ol>
<p>memory dysfunction. Science. 1982;217(4558):408-414.</p>
<ol>
<li>Perry EK, Perry RH, Blessed G, Tomlinson BE. Changes in brain cholinesterases in </li>
</ol>
<p>senile dementia of Alzheimer type. Neuropathol Appl Neurobiol. 1978;4(4):273-277.</p>
<ol>
<li>Straif K, Baan R, Grosse Y, et al. Carcinogenicity of shift-work, painting, and </li>
</ol>
<p>fire-fighting. Lancet Oncol. 2007;8(12):1065-1066.</p>
<ol>
<li>Stevens RG, Brainard GC, Blask DE, Lockley SW, Motta ME. Breast cancer and </li>
</ol>
<p>circadian disruption from electric lighting in the modern world. CA Cancer J Clin. </p>
<p>2014;64(3):207-218.</p>
<ol>
<li>Musiek ES, Xiong DD, Holtzman DM. Sleep, circadian rhythms, and the pathogenesis </li>
</ol>
<p>of Alzheimer disease. Exp Mol Med. 2015;47:e148.</p>
<ol>
<li>Gibson GE, Starkov A, Blass JP, Ratan RR, Beal MF. Cause and consequence: </li>
</ol>
<p>mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal </p>
<p>death and behavioral abnormalities in age-associated neurodegenerative diseases. </p>
<p>Biochim Biophys Acta. 2010;1802(1):122-134.</p>
<ol>
<li>Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE. Mitochondrial abnormalities </li>
</ol>
<p>in Alzheimer brain: mechanistic implications. Ann Neurol. 2005;57(5):695-703.</p>
<ol>
<li>Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce </li>
</ol>
<p>2-hydroxyglutarate. Nature. 2009;462(7274):739-744.</p>
<ol>
<li>Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive </li>
</ol>
<p>inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19(1):17-30.</p>
<ol>
<li>Vance DE, Ridgway ND. The methylation of phosphatidylethanolamine. Prog Lipid </li>
</ol>
<p>Res. 1988;27(1):61-79.</p>
<ol>
<li>
<p>Zeisel SH, Blusztajn JK. Choline and human nutrition. Annu Rev Nutr. 1994;14:269-296.</p>
</li>
<li>
<p>DeLong CJ, Shen YJ, Thomas MJ, Cui Z. Molecular distinction of phosphatidylcholine </p>
</li>
</ol>
<p>synthesis between the CDP-choline pathway and phosphatidylethanolamine methylation </p>
<p>pathway. J Biol Chem. 1999;274(42):29683-29688.</p>
<ol>
<li>Fontecave M, Atta M, Mulliez E. S-adenosylmethionine: nothing goes to waste. </li>
</ol>
<p>Trends Biochem Sci. 2004;29(5):243-249.</p>
<ol>
<li>Sieghart W, Savić MM. International Union of Basic and Clinical Pharmacology. </li>
</ol>
<p>CVI: GABA_A receptor subtype- and function-selective ligands: key issues in </p>
<p>translation to humans. Pharmacol Rev. 2018;70(4):836-878.</p>
<ol>
<li>Bettler B, Kaupmann K, Mosbacher J, Gassmann M. Molecular structure and </li>
</ol>
<p>physiological functions of GABA_B receptors. Physiol Rev. 2004;84(3):835-867.</p>
<ol>
<li>Gassmann M, Bettler B. Regulation of neuronal GABA_B receptor functions by </li>
</ol>
<p>subunit composition. Nat Rev Neurosci. 2012;13(6):380-394.</p>
<ol>
<li>Waagepetersen HS, Sonnewald U, Schousboe A. The GABA paradox: multiple roles as </li>
</ol>
<p>metabolite, neurotransmitter, and neurodifferentiative agent. J Neurochem. </p>
<p>1999;73(4):1335-1342.</p>
<ol>
<li>Schousboe A, Bak LK, Waagepetersen HS. Astrocytic control of biosynthesis and </li>
</ol>
<p>turnover of the neurotransmitters glutamate and GABA. Front Endocrinol (Lausanne). </p>
<p>2013;4:102.</p>
<ol>
<li>
<p>Petroff OA. GABA and glutamate in the human brain. Neuroscientist. 2002;8(6):562-573.</p>
</li>
<li>
<p>Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to </p>
</li>
</ol>
<p>5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. </p>
<p>2009;324(5929):930-935.</p>
<ol>
<li>Kooistra SM, Helin K. Molecular mechanisms and potential functions of histone </li>
</ol>
<p>demethylases. Nat Rev Mol Cell Biol. 2012;13(5):297-311.</p>
<ol>
<li>
<p>Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics. 2009;1(2):239-259.</p>
</li>
<li>
<p>Lithner CU, Lacor PN, Zhao WQ, et al. Disruption of neocortical histone H3 </p>
</li>
</ol>
<p>homeostasis by soluble Aβ: implications for Alzheimer's disease. Neurobiol Aging. </p>
<p>2013;34(9):2081-2090.</p>
<ol>
<li>Nakahata Y, Sahar S, Astarita G, Kaluzova M, Sassone-Corsi P. Circadian control </li>
</ol>
<p>of the NAD+ salvage pathway by CLOCK-SIRT1. Science. 2009;324(5927):654-657.</p>
<ol>
<li>Gerstner JR, Lyons LC, Wright KP Jr, et al. Cycling behavior and memory </li>
</ol>
<p>formation. J Neurosci. 2009;29(41):12824-12830.</p>
<ol>
<li>Aton SJ, Colwell CS, Harmar AJ, Waschek J, Herzog ED. Vasoactive intestinal </li>
</ol>
<p>polypeptide mediates circadian rhythmicity and synchrony in mammalian clock neurons. </p>
<p>Nat Neurosci. 2005;8(4):476-483.</p>
<ol>
<li>Moore RY, Speh JC. GABA is the principal neurotransmitter of the circadian </li>
</ol>
<p>system. Neurosci Lett. 1993;150(2):112-116.</p>
<ol>
<li>Blask DE, Dauchy RT, Sauer LA. Putting cancer to sleep at night: the </li>
</ol>
<p>neuroendocrine/circadian melatonin signal. Endocrine. 2005;27(2):179-188.</p>
<ol>
<li>Wu YH, Swaab DF. Disturbance and strategies for reactivation of the circadian </li>
</ol>
<p>rhythm system in aging and Alzheimer's disease. Sleep Med. 2007;8(6):623-636.</p>
<ol>
<li>Kang TH, Reardon JT, Kemp M, Sancar A. Circadian oscillation of nucleotide </li>
</ol>
<p>excision repair in mammalian brain. Proc Natl Acad Sci USA. 2009;106(8):2864-2867.</p>
<ol>
<li>Sarter M, Parikh V. Choline transporters, cholinergic transmission and cognition. </li>
</ol>
<p>Nat Rev Neurosci. 2005;6(1):48-56.</p>
<ol>
<li>Mesulam MM, Mufson EJ, Levey AI, Wainer BH. Cholinergic innervation of cortex by </li>
</ol>
<p>the basal forebrain: cytochemistry and cortical connections of the septal area, </p>
<p>diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in </p>
<p>the rhesus monkey. J Comp Neurol. 1983;214(2):170-197.</p>
<ol>
<li>Ylilauri MP, Voutilainen S, Lönnroos E, et al. Association of dietary choline </li>
</ol>
<p>intake with risk of incident dementia and with cognitive performance: the Kuopio </p>
<p>Ischaemic Heart Disease Risk Factor Study. Am J Clin Nutr. 2019;110(6):1416-1423.</p>
<ol>
<li>Schuller HM, Al-Wadei HA, Majidi M. GABA B receptor is a novel drug target for </li>
</ol>
<p>pancreatic cancer. Cancer. 2008;112(4):767-778.</p>
<ol>
<li>Rissman RA, De Blas AL, Armstrong DM. GABA_A receptors in aging and Alzheimer's </li>
</ol>
<p>disease. J Neurochem. 2007;103(4):1285-1292.</p>
<ol>
<li>da Costa KA, Kozyreva OG, Song J, Galanko JA, Fischer LM, Zeisel SH. Common </li>
</ol>
<p>genetic polymorphisms affect the human requirement for the nutrient choline. FASEB </p>
<p>J. 2006;20(9):1336-1344.</p>
<ol>
<li>Kohlmeier M, da Costa KA, Fischer LM, Zeisel SH. Genetic variation of folate-</li>
</ol>
<p>mediated one-carbon transfer pathway predicts susceptibility to choline deficiency </p>
<p>in humans. Proc Natl Acad Sci USA. 2005;102(44):16025-16030.</p>
<ol>
<li>Rothman DL, Behar KL, Hyder F, Shulman RG. In vivo NMR studies of the glutamate </li>
</ol>
<p>neurotransmitter flux and neuroenergetics: implications for brain function. Annu Rev </p>
<p>Physiol. 2003;65:401-427.</p>
<ol>
<li>
<p>Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol. 2013;75:685-705.</p>
</li>
<li>
<p>Levine AJ, Jenkins NA, Copeland NG. The roles of initiating truncal mutations in </p>
</li>
</ol>
<p>human cancers: the order of mutations and tumor cell type matters. Cancer Cell. </p>
<p>2019;35(1):10-15.</p>
<ol>
<li>Driver JA, Lu KP. PIN1: a new genetic link between Alzheimer's disease, cancer </li>
</ol>
<p>and aging. Curr Aging Sci. 2010;3(3):158-165.</p>
                
<div class="footer-warning">
    <strong>© IL WOONG CHOI / CODEX OF COSMOS 2025. All Rights Reserved.</strong><br>
    This work is licensed under a <a href="http://creativecommons.org/licenses/by-nc-nd/4.0/" target="_blank" style="color:#777;">Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License</a>.<br>
    Unauthorized reproduction, distribution, or modification of this material is a violation of international copyright law.<br>
    <span style="color: red;">WARNING: This site employs digital rights management (DRM) protocols. Any attempt to scrape, copy, or extract data is monitored.</span>
</div>

            </div>
            </body></html>